Holen Sie sich die Stockscreener-App
11.31
7.90%
-0.97
Vorhandelsmarkt:
10.65
-0.66
-5.84%
Schlusskurs vom Vortag:
$12.28
Offen:
$12.66
24-Stunden-Volumen:
96,839
Relative Volume:
1.39
Marktkapitalisierung:
$21.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.56M
KGV:
-0.2558
EPS:
-44.2199
Netto-Cashflow:
$-28.59M
1W Leistung:
-10.52%
1M Leistung:
+1.80%
6M Leistung:
+225.94%
1J Leistung:
-30.19%
1-Tages-Spanne:
$11.00
$12.91
1-Wochen-Bereich:
$11.00
$13.09
52-Wochen-Spanne:
$0.61
$17.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Firmenname
Briacell Therapeutics Corp
Sektor
Branche
Telefon
(604) 921-1810
Adresse
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Vergleichen Sie BCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
11.31 | 23.13M | 0 | -26.56M | -28.59M | -44.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
BriaCell reports positive data for breast cancer immunotherapy By Investing.com - Investing.com Nigeria
BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposiu - GuruFocus
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 - Investing News Network
BriaCell’s Bria-IMT Shows Promising Results in Metastatic Breast Cancer Trials - TipRanks
(BCT) Trading Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Brea - GuruFocus
BriaCell’s Phase 3 Study on Track for 2026 Data Readout - TipRanks
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - Investing News Network
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - The Manila Times
Movement Recap: Will BriaCell Therapeutics Corp Equity Warrant stock outperform Dow Jones indexJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
BriaCell Therapeutics (BCTXZ) Stock Analysis Report | Financials & Insights - Benzinga
BriaCell Therapeutics : Investor Presentation (1Dec2025 Investor Presentation) - marketscreener.com
Will BriaCell Therapeutics Corp. Equity Warrant stock outperform Dow Jones indexQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
BriaCell to present positive breast cancer therapy data at SABCS By Investing.com - Investing.com Australia
BriaCell Therapeutics (BCTXW) Stock Analysis Report | Financials & Insights - Benzinga
BriaCell Unveils Promising Clinical Data at 2025 SABCS - TipRanks
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 - Investing News Network
BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 S - GuruFocus
BriaCell to present positive breast cancer therapy data at SABCS - Investing.com
BriaCell (Nasdaq: BCTX) shares survival, biomarker data; Phase 3 interim readout 1H2026 - Stock Titan
Can BriaCell Therapeutics Corp. stock hit analyst price targetsMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
(BCT) Strategic Investment Report (BCT:CA) - news.stocktradersdaily.com
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
BriaCell files subsidiary financials and analysis with Canadian regulators By Investing.com - Investing.com Nigeria
BriaCell files subsidiary financials and analysis with Canadian regulators - Investing.com
BriaCell Therapeutics Corp Subsidiary Files Financial Statements - TradingView
(BCT) Comprehensive Trading Strategy Report (BCT:CA) - news.stocktradersdaily.com
What analysts say about BriaCell Therapeutics Corp stockEquity Performance Review & Fast Growing Portfolio Trading - earlytimes.in
BCTXZ Insider Trading - Quiver Quantitative
BriaCell Therapeutics Corp. (BCTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BriaCell Therapeutics to Present Promising Clinical Data at SABCS 2025 - The Globe and Mail
BriaCell to present positive cancer treatment data at breast cancer symposium By Investing.com - Investing.com Nigeria
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025 - Investing News Network
BriaCell to present positive cancer treatment data at breast cancer symposium - Investing.com
BriaCell Therapeutics Brief: Says to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS 2025 - marketscreener.com
How to Take Advantage of moves in (BCT) (BCT:CA) - news.stocktradersdaily.com
BriaCell Expands Phase 3 Study in Metastatic Breast Cancer - MSN
What analysts say about BriaCell Therapeutics Corp Equity Warrant stockDividend Stability Analysis & Exceptional Capital Trading - earlytimes.in
BriaCell to Present Key Clinical Data at SABCS 2025 - MSN
BriaCell and Receptor.AI Partner on AI- driven Small Molecule Cancer Therapeutics - MarketScreener
BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development - GuruFocus
Briacell and Receptor.AI to collaborate on AI driven small molecule cancer therapeutics - MarketScreener
BriaCell and Receptor.AI Collaborate on AI-Driven Cancer Therapeutics - TipRanks
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - The Manila Times
How BriaCell Therapeutics Corp. stock valuations compare to rivalsProfit Target & AI Forecasted Stock Moves - newser.com
Why analysts maintain buy rating on BriaCell Therapeutics Corp. (8BT0) stockSwing Trade & Trade Opportunity Analysis - newser.com
How buyback programs support BriaCell Therapeutics Corp. (8BT0) stock - newser.com
Finanzdaten der Briacell Therapeutics Corp-Aktie (BCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):